LON:MATE JPMorgan Multi-Asset Growth & Income (MATE) Share Price, News & Analysis → Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad) Free MATE Stock Alerts GBX 103 -0.84 (-0.81%) (As of 03/25/2024) Add Compare Share Share Today's Range 103▼ 10350-Day Range 97.37▼ 103.8452-Week Range 85.92▼ 104.96VolumeN/AAverage Volume78,261 shsMarket Capitalization£75.67 millionP/E RatioN/ADividend Yield4.85%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendHeadlinesStock AnalysisChartCompetitorsDividendHeadlines Get JPMorgan Multi-Asset Growth & Income alerts: Email Address Ad Behind the MarketsTiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> About JPMorgan Multi-Asset Growth & Income Stock (LON:MATE)JPMorgan Multi-Asset Trust PLC was founded in 2017 and is based in London, United Kingdom.Read More MATE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MATE Stock News HeadlinesApril 16, 2024 | insidermonkey.comJPMorgan Chase & Co. (NYSE:JPM) Q1 2024 Earnings Call TranscriptApril 1, 2024 | msn.comHousing market deep freeze begins to thaw, JPMorgan says. Here’s what they seeApril 19, 2024 | Behind the Markets (Ad)Tiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.February 12, 2024 | msn.comTreating China as ‘un-investable’ would be ‘wide of the mark,’ JPMorgan strategist saysFebruary 1, 2024 | msn.comJ.P. Morgan & Fidelity Reports: Realistic Retirement Rate of Return By Asset ClassJanuary 25, 2024 | msn.comMoney market funds keep growing despite expected Fed cuts, JPMorgan strategists sayJanuary 19, 2024 | bizjournals.comThe Bay Area is positioned for growth and refreshed investments in 2024January 19, 2024 | seekingalpha.comJPMorgan Chase: Consider Buying With A Downward ForecastApril 19, 2024 | Behind the Markets (Ad)Tiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.January 17, 2024 | msn.comJPMorgan says attempts by hackers are on the rise and it's spending $15 billion partly to defend against cybercrimeJanuary 14, 2024 | msn.comJPMorgan Chase sees 8% increase in expenses in '24 on expansion, inflation, techJanuary 12, 2024 | msn.comJPMorgan 2024 net interest income forecast tops estimatesJanuary 10, 2024 | bloomberg.comJPMorgan Asset Says Fed Rate Cuts May Be Steeper Than ExpectedJanuary 5, 2024 | finance.yahoo.comU.S. Large-Cap, Japan Stocks Favored, JPMorgan SaysJanuary 4, 2024 | msn.comHow multi-asset fund investment may support you in uncertain financial times?December 18, 2023 | markets.businessinsider.comCritical Insights From JPMorgan Chase Analyst Ratings: What You Need To KnowDecember 15, 2023 | seekingalpha.comMulti-Asset Income Investing In A 2024 SlowdownDecember 13, 2023 | msn.comJPMorgan came to the rescue in 2023; will earnings lose luster in 2024?December 6, 2023 | msn.comThe recession dilemma: Why J.P. Morgan Asset Management isn't playing the 'if' and 'when' gameDecember 5, 2023 | msn.comPrepare for the S&P 500 to plunge 23% by mid-2024 - and the US economy to sink into recession, JPMorgan's top charts guru saysNovember 7, 2023 | ca.sports.yahoo.comThe stock market's latest rally is about to fizzle amid a barrage of concerns, JPMorgan saysNovember 3, 2023 | msn.comWe don't think the Fed will be hiking rates again, says JPMorgan Asset Management's Kelsey BerroOctober 18, 2023 | bloomberg.comJPMorgan Says 60/40 Portfolio Far From Dead, Set to Trounce CashOctober 14, 2023 | msn.comJPMorgan Chase tops profit expectations on higher rates, benign creditOctober 13, 2023 | msn.comJPMorgan Chase Q3 2023 earnings beat forecasts, net income +35% to $13.2bnOctober 13, 2023 | msn.comJPMorgan Reports Better-Than-Expected Q3 Earnings: A Comprehensive AnalysisOctober 7, 2023 | msn.comJPMorgan Chase: A 6% Yield On Preferred Shares With Potential Capital GainsSee More Headlines Receive MATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for JPMorgan Multi-Asset Growth & Income and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 2/9 Dividend12/21/2023Dividend Payable2/09/2024Ex-Dividend for 3/22 Dividend2/22/2024Dividend Payable3/22/2024Today4/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorFinancial Services Industry Asset Management Sub-IndustryN/A Current SymbolLON:MATE CUSIPN/A CIKN/A Webam.jpmorgan.com Phone4420-7742-6000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares73,470,000Free FloatN/AMarket Cap£75.67 million OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key CompetitorsMobeus Income & Growth 4 VCTLON:MIG4AgronomicsLON:ANICMIGO Opportunities TrustLON:MIGOSchroder BSC Social Impact TrustLON:SBSIabrdn Japan Investment TrustLON:AJITView All Competitors MATE Stock Analysis - Frequently Asked Questions How have MATE shares performed in 2024? JPMorgan Multi-Asset Growth & Income's stock was trading at GBX 97 at the start of the year. Since then, MATE shares have increased by 6.2% and is now trading at GBX 103. View the best growth stocks for 2024 here. How often does JPMorgan Multi-Asset Growth & Income pay dividends? What is the dividend yield for JPMorgan Multi-Asset Growth & Income? JPMorgan Multi-Asset Growth & Income declared a dividend on Thursday, February 15th. Stockholders of record on Thursday, February 22nd will be paid a dividend of GBX 1.20 per share on Friday, March 22nd. This represents a yield of 1.21%. The ex-dividend date is Thursday, February 22nd. The official announcement can be accessed at this link. Read our dividend analysis for MATE. Is JPMorgan Multi-Asset Growth & Income a good dividend stock? JPMorgan Multi-Asset Growth & Income (LON:MATE) pays an annual dividend of GBX 5 per share and currently has a dividend yield of 5.38%. MATE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for MATE. How do I buy shares of JPMorgan Multi-Asset Growth & Income? Shares of MATE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:MATE) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTIYour Money is Not SafeAmerican AlternativeHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceSHOCKING Crypto Leak…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JPMorgan Multi-Asset Growth & Income Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.